Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):546–555. doi: 10.1038/sj.bjc.6690390

Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression

G B Baretton 1, U Klenk 1, J Diebold 1, N Schmeller 2, U Löhrs 1
PMCID: PMC2362324  PMID: 10408865

Abstract

The molecular mechanisms leading to androgen-independent growth in prostate cancer (PC) are poorly understood. Androgen deprivation therapy (ADT) results physiologically in a decrease in proliferation and an increase in programmed cell death (PCD)/apoptosis. The aim of our study was to get more insight into these processes in prostatic carcinomas before and after ADT. For this purpose, immunohistologic staining for the androgen receptor (AR) molecule, the Ki-67 antigen, the bcl-2 oncoprotein, the p53 protein and its physiologic effector, p21/WAF1, was performed on archival material. PCD was visualized by enzymatic detection of DNA fragmentation. Specimens from 69 PC patients after ADT were studied in correlation to histopathology and prognosis. In 42 cases, corresponding tumour tissue from the untreated primary tumours could be analysed comparatively. Before ADT, histologic grade was associated with Ki-67 index (P < 0.0001, Spearman correlation) and PCD rate (P < 0.05, Spearman correlation). Ki-67 index correlated with PCD rate (P < 0.05, Spearman correlation) and p21/WAF1 expression (P < 0.01, Fisher's exact test). p21/WAF1 expression was the only statistically significant prognostic factor for shorter survival (P < 0.002, log-rank test). All p21/WAF1-positive cases showed high Ki-67 index and high histologic grade. After ADT, loss of AR expression was associated with high Ki-67 index, whereas histologic signs of regression correlated negatively with Ki-67 index (P < 0.001, Pearson χ2 test). p21/WAF1 expression increased significantly (P < 0.02, McNemar test) and correlated with p53 accumulation (P < 0.0001, Pearson χ2 test). Most significant prognostic parameter after conventional ADT was high-rate p21/WAF1 expression (> 50% of tumour cells; P < 0.00001, log-rank test). This study demonstrates that p21/WAF1 overexpression before and after ADT characterizes a subgroup of advanced PC with paradoxically high proliferation rate and significantly worse clinical outcome. This finding might be clinically useful for planning therapy in these patients. © 1999 Cancer Research Campaign

Keywords: prostate cancer pathology, androgen-independence, proliferation, apoptosis, p21/WAF1/CIP1 immunohistochemistry, prognosis

Full Text

The Full Text of this article is available as a PDF (223.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ansari B., Coates P. J., Greenstein B. D., Hall P. A. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol. 1993 May;170(1):1–8. doi: 10.1002/path.1711700102. [DOI] [PubMed] [Google Scholar]
  2. Blagosklonny M. V., Prabhu N. S., El-Deiry W. S. Defects in p21WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res. 1997 Jan 15;57(2):320–325. [PubMed] [Google Scholar]
  3. Bookstein R., MacGrogan D., Hilsenbeck S. G., Sharkey F., Allred D. C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 1993 Jul 15;53(14):3369–3373. [PubMed] [Google Scholar]
  4. Bubendorf L., Sauter G., Moch H., Jordan P., Blöchlinger A., Gasser T. C., Mihatsch M. J. Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol. 1996 May;148(5):1557–1565. [PMC free article] [PubMed] [Google Scholar]
  5. Chen X., Bargonetti J., Prives C. p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res. 1995 Oct 1;55(19):4257–4263. [PubMed] [Google Scholar]
  6. Civantos F., Marcial M. A., Banks E. R., Ho C. K., Speights V. O., Drew P. A., Murphy W. M., Soloway M. S. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer. 1995 Apr 1;75(7):1634–1641. doi: 10.1002/1097-0142(19950401)75:7<1634::aid-cncr2820750713>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  7. Colombel M., Symmans F., Gil S., O'Toole K. M., Chopin D., Benson M., Olsson C. A., Korsmeyer S., Buttyan R. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993 Aug;143(2):390–400. [PMC free article] [PubMed] [Google Scholar]
  8. Eastham J. A., Stapleton A. M., Gousse A. E., Timme T. L., Yang G., Slawin K. M., Wheeler T. M., Scardino P. T., Thompson T. C. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res. 1995 Oct;1(10):1111–1118. [PubMed] [Google Scholar]
  9. Ellis P. A., Lonning P. E., Borresen-Dale A., Aas T., Geisler S., Akslen L. A., Salter I., Smith I. E., Dowsett M. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer. 1997;76(4):480–485. doi: 10.1038/bjc.1997.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Erber R., Klein W., Andl T., Enders C., Born A. I., Conradt C., Bartek J., Bosch F. X. Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer. 1997 Aug 22;74(4):383–389. doi: 10.1002/(sici)1097-0215(19970822)74:4<383::aid-ijc4>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  11. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  12. Gao X., Chen Y. Q., Wu N., Grignon D. J., Sakr W., Porter A. T., Honn K. V. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene. 1995 Oct 5;11(7):1395–1398. [PubMed] [Google Scholar]
  13. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992 Nov;119(3):493–501. doi: 10.1083/jcb.119.3.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gleason D. F. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966 Mar;50(3):125–128. [PubMed] [Google Scholar]
  15. Gleason D. F. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992 Mar;23(3):273–279. doi: 10.1016/0046-8177(92)90108-f. [DOI] [PubMed] [Google Scholar]
  16. Gleason D. F., Mellinger G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974 Jan;111(1):58–64. doi: 10.1016/s0022-5347(17)59889-4. [DOI] [PubMed] [Google Scholar]
  17. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., Kaibara N., Ito H. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer. 1997 Jun 1;79(11):2067–2072. doi: 10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  18. Harada N., Gansauge S., Gansauge F., Gause H., Shimoyama S., Imaizumi T., Mattfeld T., Schoenberg M. H., Beger H. G. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer. 1997;76(3):299–305. doi: 10.1038/bjc.1997.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Isaacs J. T., Furuya Y., Berges R. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol. 1994 Oct;5(5):391–400. [PubMed] [Google Scholar]
  20. Klocker H., Culig Z., Hobisch A., Cato A. C., Bartsch G. Androgen receptor alterations in prostatic carcinoma. Prostate. 1994 Nov;25(5):266–273. doi: 10.1002/pros.2990250506. [DOI] [PubMed] [Google Scholar]
  21. Korsmeyer S. J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 1992 Aug 15;80(4):879–886. [PubMed] [Google Scholar]
  22. Korsmeyer S. J. Bcl-2: a repressor of lymphocyte death. Immunol Today. 1992 Aug;13(8):285–288. doi: 10.1016/0167-5699(92)90037-8. [DOI] [PubMed] [Google Scholar]
  23. Krajewska M., Krajewski S., Epstein J. I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J. C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996 May;148(5):1567–1576. [PMC free article] [PubMed] [Google Scholar]
  24. Kubota Y., Shuin T., Uemura H., Fujinami K., Miyamoto H., Torigoe S., Dobashi Y., Kitamura H., Iwasaki Y., Danenberg K. Tumor suppressor gene p53 mutations in human prostate cancer. Prostate. 1995 Jul;27(1):18–24. doi: 10.1002/pros.2990270105. [DOI] [PubMed] [Google Scholar]
  25. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  26. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  27. Li Y., Jenkins C. W., Nichols M. A., Xiong Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 1994 Aug;9(8):2261–2268. [PubMed] [Google Scholar]
  28. Lukas J., Groshen S., Saffari B., Niu N., Reles A., Wen W. H., Felix J., Jones L. A., Hall F. L., Press M. F. WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol. 1997 Jan;150(1):167–175. [PMC free article] [PubMed] [Google Scholar]
  29. Maelandsmo G. M., Holm R., Fodstad O., Kerbel R. S., Flørenes V. A. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996 Dec;149(6):1813–1822. [PMC free article] [PubMed] [Google Scholar]
  30. McDonnell T. J., Troncoso P., Brisbay S. M., Logothetis C., Chung L. W., Hsieh J. T., Tu S. M., Campbell M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 Dec 15;52(24):6940–6944. [PubMed] [Google Scholar]
  31. Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994 Jul 1;54(13):3391–3395. [PubMed] [Google Scholar]
  32. Miyamoto K. K., McSherry S. A., Dent G. A., Sar M., Wilson E. M., French F. S., Sharief Y., Mohler J. L. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol. 1993 May;149(5):1015–1019. doi: 10.1016/s0022-5347(17)36284-5. [DOI] [PubMed] [Google Scholar]
  33. Navone N. M., Troncoso P., Pisters L. L., Goodrow T. L., Palmer J. L., Nichols W. W., von Eschenbach A. C., Conti C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst. 1993 Oct 20;85(20):1657–1669. doi: 10.1093/jnci/85.20.1657. [DOI] [PubMed] [Google Scholar]
  34. Peterziel H., Culig Z., Stober J., Hobisch A., Radmayr C., Bartsch G., Klocker H., Cato A. C. Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer. 1995 Nov 15;63(4):544–550. doi: 10.1002/ijc.2910630415. [DOI] [PubMed] [Google Scholar]
  35. Piffko J., Bankfalvi A., Ofner D., Joos U., Böcker W., Schmid K. W. Immunohistochemical detection of p53 protein in archival tissues from squamous cell carcinomas of the oral cavity using wet autoclave antigen retrieval. J Pathol. 1995 May;176(1):69–75. doi: 10.1002/path.1711760111. [DOI] [PubMed] [Google Scholar]
  36. Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis. Nature. 1997 Sep 18;389(6648):300–305. doi: 10.1038/38525. [DOI] [PubMed] [Google Scholar]
  37. Shurbaji M. S., Kalbfleisch J. H., Thurmond T. S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 1995 Jan;26(1):106–109. doi: 10.1016/0046-8177(95)90122-1. [DOI] [PubMed] [Google Scholar]
  38. Stewart B. W. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst. 1994 Sep 7;86(17):1286–1296. doi: 10.1093/jnci/86.17.1286. [DOI] [PubMed] [Google Scholar]
  39. Suzuki H., Akakura K., Komiya A., Aida S., Akimoto S., Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate. 1996 Sep;29(3):153–158. doi: 10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  40. Taplin M. E., Bubley G. J., Shuster T. D., Frantz M. E., Spooner A. E., Ogata G. K., Keer H. N., Balk S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995 May 25;332(21):1393–1398. doi: 10.1056/NEJM199505253322101. [DOI] [PubMed] [Google Scholar]
  41. Trapman J., Brinkmann A. O. The androgen receptor in prostate cancer. Pathol Res Pract. 1996 Jul;192(7):752–760. doi: 10.1016/S0344-0338(96)80097-5. [DOI] [PubMed] [Google Scholar]
  42. Trotter M. J., Tang L., Tron V. A. Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol. 1997 May;24(5):265–271. doi: 10.1111/j.1600-0560.1997.tb00790.x. [DOI] [PubMed] [Google Scholar]
  43. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinänen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995 Apr;9(4):401–406. doi: 10.1038/ng0495-401. [DOI] [PubMed] [Google Scholar]
  44. Visakorpi T., Kallioniemi O. P., Heikkinen A., Koivula T., Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst. 1992 Jun 3;84(11):883–887. doi: 10.1093/jnci/84.11.883. [DOI] [PubMed] [Google Scholar]
  45. Wang A., Yoshimi N., Ino N., Tanaka T., Mori H. WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol. 1997;123(2):118–123. doi: 10.1007/BF01269890. [DOI] [PubMed] [Google Scholar]
  46. Wertz I. E., Deitch A. D., Gumerlock P. H., Gandour-Edwards R., Chi S. G., de Vere White R. W. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol. 1996 Jun;27(6):573–580. doi: 10.1016/s0046-8177(96)90164-1. [DOI] [PubMed] [Google Scholar]
  47. Westin P., Stattin P., Damber J. E., Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol. 1995 Jun;146(6):1368–1375. [PMC free article] [PubMed] [Google Scholar]
  48. el-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 1;54(5):1169–1174. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES